logo-loader

Oxford Cannabinoid Technologies first dosing a "major achievement" - Proactive Research Analyst

Published: 20:42 27 Jul 2023 AEST

Proactive Research Analyst Daniel Appiah speaks to Thomas Warner at the London Studio after publishing a new research note on Oxford Cannabinoid Technologies Holdings PLC (LSE:OCTP, OTCQB:OCTHF)

The pharmaceutical group announced on 27 July that it has commenced its phase I clinical trial for lead drug candidate, OCT461201, marking the administration of the first human dose.

Appiah describes the news as a "major achievement" for Oxford Cannabinoid Technologies, highlighting its transformation from a development company into being a clinical company He also gives an overview of other recent news from the business. For more details, read Daniel's full report by clicking the link provided.

Click here to read the report

Parbo Resources uncovers new greenstone belt at Mount Padbury

Parbo Resources (ASX:PRB) CEO Tim Campbell talked with Proactive's Stephen Gunnion about maiden reverse circulation (RC) drilling results at the Mount Padbury gold project, where drilling has confirmed greenstone beneath previously mapped granite at the GoldenEye prospect, from just 44 metres...

5 hours, 44 minutes ago